+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Direct and metabolism-dependent cytochrome P45 inhibition assays for evaluating drug–drug interactions

Direct and metabolism-dependent cytochrome P45 inhibition assays for evaluating drug–drug interactions

We developed methods for evaluating the ntial inhibition of human cytochrome P45 (CYP) enzymes, including CYP1A2, CYP2A6, CYP2B6, CYP2?C9, CYP2?C19, CYP2D6, CYP2E1 and CYP3A4, using pooled human liver microsomes (HLMs). The CYP inhibition assay used substrate cocktail sets [set A: phenacetin for CYP1A2, coumarin for CYP2A6, (S)-(+)-mephenytoin for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4; set B: bupropion for CYP2B6, tolbutamide for CYP2C9, chlorzoxazone for CYP2E1, and testosterone for CYP3A4] with quantitation by liquid chromatography tandem mass spectrometry. A direct inhibition assay was performed with the substrate cocktails without ?-nicotinamide adenine dinucleotide phosphate (NADPH) pre-incubation, and a metabolism-dependent inhibition (MDI) assay was performed after 3?min of pre-incubation with NADPH in HLMs. MDI was identified based on the half-maximal inhibitory concentration (IC5) shifts. The IC5 values of the direct inhibitors determined using the probe substrate cocktails were in good agreement with previously reported values. Eight metabolism-dependent inhibitors including furafylline, 8-methoxypsoralen, tienilic acid, ticlopidine, fluoxetine, paroxetine, disulfiram and verapamil against CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, respectively, resulted in significant IC5 shifts (?2.5-fold) after pre-incubation. Thus, these CYP inhibition assays are considered to be useful tools for evaluating both direct inhibition and MDI at an early stage of the drug discovery and development process.

(PDF emailed within 1 workday: $29.90)

Accession: 036384953

Download citation: RISBibTeXText

Related references

Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. Journal of Applied Toxicology 33(2): 100-108, 2013

Direct and metabolism-dependent cytochrome P45 inhibition assays for evaluating drug–rug interactions. 2011

Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. Chemico-Biological Interactions 198(1-3): 49-56, 2012

Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metabolism and Pharmacokinetics 24(6): 500-510, 2010

Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metabolism and Pharmacokinetics 25(1): 28-47, 2010

Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metabolism and Drug Interactions 21(3-4): 163-185, 2006

Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Annals of PharmacoTherapy 39(6): 1064-1072, 2005

Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharmaceutical Research 25(5): 1063-1074, 2007

High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals 43(11): 1670-1678, 2016

Evaluations of in vitro metabolism, drug-drug interactions mediated by reversible and time-dependent inhibition of CYPs, and plasma protein binding of MMB4 DMS. International Journal of Toxicology 32(4 Suppl): 75s-87s, 2014

Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochemical Pharmacology 82(6): 681-691, 2011

Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharmaceutical Research 29(7): 1960-1976, 2012